Enzalutamide prostate cancer drug

Enzalutamide prostate cancer drug

C019/9774 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 50.1MB

Downloadable file size: 2.3MB

Price image Pricing

Please login to use the price calculator


Restrictions: Editorial use only

Caption: Enzalutamide prostate cancer drug. This new hormone therapy drug, developed by Medivation and marketed by Astellas, was approved for use in the USA in 2012. It has also been licensed for use in the UK. It is used in cases of advanced prostate cancer that are no longer responding to standard hormone therapy or chemotherapy.

Release details: Model release not required. Property release not available.

Keywords: 2013, 21st century, 40 mg, 40 milligram, advanced, brand, brandname, drug, enzalutamide, healthcare, mdv3100, medical, medicine, new, no-one, nobody, oncological, oncology, oral, packaging, packet, pharmaceutical, pharmaceutics, pharmacological, pharmacology, prostate cancer, soft capsules, treatment, xtandi

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.